# Efficacy of oral viscous budesonide to reduce dilation treatment after esophageal atresia repair: a retrospective study

## TL;DR

This study shows that oral viscous budesonide can significantly reduce the need for repeated esophageal dilation in children after esophageal atresia repair.

## Contribution

The study demonstrates that OVB prolongs the time between dilation treatments and reduces symptom recurrence in pediatric EA patients.

## Key findings

- 13 out of 19 patients did not require further dilations after OVB treatment.
- Median time between dilations increased from 2 to 30 months with OVB.
- Time to dysphagia relapse increased from 1 to 18 months with OVB.

## Abstract

Anastomotic stricture is a common complication following esophageal atresia (EA) repair, substantially affecting the patient’s quality of life (QoL). Multiple dilations are often required to maintain the appropriate diameter of the esophagus, leading to ongoing challenges. The aim of this study is to assess the efficacy of oral viscous budesonide (OVB) in prolonging the time between symptom recurrence and subsequent dilation.

We carried out a retrospective single-center study for pediatric patients (0–18 years) who had undergone recurrent esophageal dilations (≥3) following EA repair and initiated treatment with OVB (1 mg/day <10 years, otherwise 2 mg/day). Efficacy of treatment was determined by assessing a dysphagia symptom score (DSS) ≤1 for at least 3 months. Recurrence time to dysphagia and dilation were analyzed according to Kaplan-Meier method.

Of 29 patients screened, 19 were enrolled: 19/19 were responsive to OVB and 13/19 (68%) didn’t required further dilations. The median time between dilations was significantly prolonged compared to the pre-treatment period [30 months vs 2 months; p<0.01] as well as the time to dysphagia relapse [18 months vs 1 month; p<0.01].

Topical budesonide has proven to be an effective treatment for recurrent esophageal stricture in repaired EA. Further investigation is required to assess the long-term sustained response of symptoms to topical steroids.